Results 11 to 20 of about 3,798 (162)

Terlipressin Induced Severe Hyponatremia

Prague Medical Report, 2016
Terlipressin is a vasopressin analogue used for its vasoconstrictor effect in the treatment of variceal bleeding. Despite its good safety profile compared to vasopressin, some adverse reactions may occur during its use – e.g. hyponatremia.
Martin Šíma, Miroslav Pokorný, František Paďour, Ondřej Slanař   +3 more
doaj   +2 more sources

Prolonged Terlipressin Therapy as a Bridge to Curative TIPS for HRS-AKI in a Nontransplant Candidate. [PDF]

Case Reports Hepatol
Hepatorenal syndrome–acute kidney injury (HRS–AKI) is a severe complication of advanced cirrhosis with high mortality and limited treatment options. Terlipressin is currently the only FDA‐approved therapy for HRS, though recurrence is common upon discontinuation in patients without access to liver transplantation.
Reidy D, Jesudian A, Salerno D, Lucero C.   +3 more
europepmc   +2 more sources

Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. [PDF]

Liver Int
ABSTRACT Background & Aims Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of decompensated cirrhosis. The US Food and Drug Administration approved terlipressin use for HRS‐AKI based on the CONFIRM study, which demonstrated a significant improvement in HRS reversal with terlipressin versus placebo.
Rockey DC, Gordon F, Thuluvath PJ, Victor D, Kemmer N, Cardoza S, Jamil K, Frederick RT.   +7 more
europepmc   +2 more sources

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. [PDF]

Aliment Pharmacol Ther
In a pooled analysis, bradycardia was observed in 6% of terlipressin‐treated patients but rarely required a dose interruption or reduction. Arrhythmia serious adverse event incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin ...
Bajaj JS, Kwo P, Pappas SC, O'Leary JG, Jamil K, Cardoza S, Wong F.   +6 more
europepmc   +2 more sources

Terlipressin‐induced skin necrosis in cirrhotic patients—A case report and comprehensive literature review [PDF]

Clinical Case Reports
Key Clinical Message The occurrence of terlipressin‐induced skin necrosis in cirrhotic patients is a rare but serious adverse event that warrants further investigation.
Ashraf I. Ahmed, Muhammad Zain Kaleem, Shahem Abbarh, Haider Hussein Barjas, Abdellatif Ismail, Mhd Kutaiba Albuni, Bisher Sawaf   +6 more
doaj   +2 more sources

Challenges in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes. [PDF]

JGH Open
ABSTRACT Background Treatments for hepatorenal syndrome with acute kidney injury (HRS‐AKI) that are not FDA‐approved have been widely used in the United States (US) with variable outcomes. This study describes the practice patterns, outcomes, and healthcare utilization around vasopressor use before terlipressin approval in 2022. Methods A retrospective
Sanyal AJ, Reddy KR, Brown KA, Landis CS, Cullaro G, Huang X, Kelkar SS, Raina R, Corman S, Kebede N, Edmundson P, Jamil K, Allegretti AS.   +12 more
europepmc   +2 more sources

Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging [PDF]

JHEP Reports
Background & aims: Terlipressin improves renal function in ∼40% of patients with hepatorenal syndrome–acute kidney injury (HRS-AKI). Nonetheless, the pathophysiological mechanisms of terlipressin remain unclear.
Karen Vagner Danielsen, Jens Dahlgaard Hove, Puria Nabilou, Thit Mynster Kronborg, Signe Wiese, Hartwig Roman Siebner, Robert Scott, Susan T. Francis, Guruprasad P. Aithal, Søren Møller, Flemming Bendtsen   +10 more
doaj   +2 more sources

The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review [PDF]

BMC Anesthesiology
Background Intraoperative hypotension is a recognized risk factor for delayed graft function (DGF) after kidney transplantation and may compromise both short- and long-term allograft outcomes.
Wen-He Yang, Xin-Lu Chang, Liang Zhang, Lei Wan, Yi Cheng, Yi-Chen Zhu, Fu-Shan Xue   +6 more
doaj   +2 more sources

Effectiveness of terlipressin for prevention of complications after major liver resection - A randomized placebo-controlled trial. [PDF]

, 2020
BACKGROUND Elevated portal pressure in response to major liver resection is associated with impaired liver regeneration and increased postoperative complications.
Perrodin, Stéphanie, Candinas, Daniel, Beldi, Guido, Kohler, Andreas, De Gottardi, Andrea   +4 more
core   +2 more sources

Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico

Annals of Hepatology, 2009
Introduction. Type 1 hepatorenal syndrome (HRS) is a functional renal failure that complicates end-stage cirrhosis. The vasopressin analogue terlipressin has been associated with improved renal function in patients with type 1 HRS.Aim.
Linda E. Muñoz, Eliud G. Alcalá, Paula Cordero, Manuel A. Martinez, Nathalie Y. Vázquez, Susana Galindo, Eduardo Mendoza, José J. Segura   +7 more
doaj   +1 more source